ABAXIS Realigns North American Medical Sales and Marketing

UNION CITY, Calif., April 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq:
ABAX), a medical products company manufacturing point-of-care blood analysis
instruments for both the medical and veterinary markets, announced a
reorganization of its North American sales and marketing organization
resulting from a strategic review of the company's medical business. As a
part of this reorganization, Christopher M. Bernard, Vice President of North
American Medical Sales and Marketing, has ceased to be an employee of the
company.

Abaxis' Medical Area Sales Directors, Mike Petrunich and Matt Rapp, will
continue to be responsible for managing and growing the field sales teams.
Rick Betts, Director of Medical Marketing, will coordinate their efforts with
the in-house marketing team and all will report to Clint Severson, chief
executive officer, until a successor to Mr. Bernard is named. The Company has
hired and retained a recruiting firm to find a successor; eligible candidates
could come from inside or outside the company.

About Abaxis
Abaxis develops, manufactures and markets portable blood analysis systems for
use in any veterinary or human patient-care setting to provide clinicians with
rapid blood constituent measurements. The system consists of a compact, 5.1
kilogram (11.2 pounds), portable analyzer and a series of single-use plastic
discs, called reagent discs that contain all the chemicals required to perform
a panel of up to 13 tests on veterinary patients and 14 tests on human
patients. The system can be operated with minimal training and performs
multiple routine tests on whole blood, serum or plasma samples. The system
provides test results in less than 12 minutes with the precision and accuracy
equivalent to a clinical laboratory analyzer.

Safe Harbor
This press release includes statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Abaxis claims the protection of the safe-harbor for forward-looking
statements contained in the Reform Act. Specific forward-looking statements
contained in this press release are subject to risks and uncertainties
including, but not limited to, risks and uncertainties related to the
company's ability to recruit and retain sales and marketing personnel, the
market acceptance of the Company's products and the continuing development of
its products, risks associated with manufacturing and distributing its
products on a commercial scale, risks associated with entering the human
diagnostic market on a larger scale, general market conditions, competition
and other risks detailed from time to time in Abaxis' periodic reports filed
with the United States Securities and Exchange Commission. Forward-looking
statements speak only as of the date the statement was made. Abaxis does not
undertake and specifically disclaims any obligation to update any
forward-looking statements.

Contact: Clint Severson Lytham Partners, LLC
Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz
Abaxis, Inc. 602-889-9700
510-675-6500

SOURCE Abaxis, Inc.

Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or
Joe Dorame, Robert Blum, or Joe Diaz, all of Lytham Partners, LLC,
+1-602-889-9700, for Abaxis, Inc.